KarXT

KarXT 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Alzheimer Disease、Psychosis Associated With Alzheimer's Disease。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 KarXT 研究

• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

  III 期招募中美国BulgariaCroatiaCzechiaNCT05511363

• Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

  III 期招募中美国Argentina比利时BrazilNCT05980949

• Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

  III 期招募中美国ArgentinaBulgariaCzechiaNCT07686263

• A Study to Evaluate the Effect of KarXT on Urological Safety

  IV 期招募中美国NCT07221877

• Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)

  不适用招募中美国NCT07101094

• A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT

  I 期招募中美国NCT07061288

• A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

  III 期招募中美国中国CroatiaIndiaNCT06951711

• A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

  III 期招募中美国澳大利亚加拿大法国NCT07424404

• A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC Reference Following Single Doses, Explore the Effect of Food After Multiple Doses of Selected Prototypes, and Evaluate Alternative Formulations of KarX and KarXT Following Single and Multiple Ascending Doses

  I 期招募中英国NCT07063342

• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)

  III 期招募中美国Argentina澳大利亚BrazilNCT06976203

• A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

  III 期招募中美国Argentina比利时BrazilNCT06585787

• A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

  III 期招募中美国ArgentinaChileCzechiaNCT07011745

• A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

  III 期招募中美国ArgentinaBrazilBulgariaNCT06937229

• A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia

  III 期招募中日本NCT06882785

• A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

  III 期招募中美国Argentina澳大利亚BulgariaNCT06951698

• A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

  III 期招募中美国比利时加拿大ChileNCT06126224

• A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia

  I 期 / II 期招募中美国NCT07423546

• Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

  不适用招募中美国NCT07379827

• A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease

  III 期招募中美国Argentina澳大利亚BrazilNCT06976216

• A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)

  III 期招募中美国Colombia日本RomaniaNCT07288567

• A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

  III 期招募中美国Argentina澳大利亚BulgariaNCT06929273

• A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

  III 期招募中美国澳大利亚加拿大日本NCT06947941

• Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers

  IV 期招募中美国NCT07681076

• A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

  III 期招募中美国ArgentinaBulgaria中国NCT07140913

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。